Quick Dispatch:
Your soul trial oral semaglutide cardiovascular outcomes nejm 2025 results GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and #obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your soul trial oral semaglutide cardiovascular outcomes nejm 2025 results GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and #obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read ships.
Need Help?
Questions about soul trial oral semaglutide cardiovascular outcomes nejm 2025 results GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and #obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for soul trial oral semaglutide cardiovascular outcomes nejm 2025 results GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and #obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read in your area.
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
29.29
💥Soul study group recently shared the result of their study :✔️ Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes @NEJM 🟡 n=9650 🟡 42.4 %had history of CKD 🟡 Majority
23.93
Oral semaglutide found to lower risk of heart failure events in people with type 2 diabetes
26.32
Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial
20.73
SOUL (Semaglutide cardiOvascular oUtcomes triaL) in individuals with
22.36
An oral formulation of semaglutide lowered the risk major adverse cardiovascular events by 14% in four years, with no change in safety profile compared to placebo, according to the SOUL study. #ACC25
20.00
Trial Scorecard: SOUL
20.04
